MICROLUMIX
See us at WHX Dubai 2026 (formerly Arab Health) · Booth: S11.E50,S11.E51,S11.E52,S11.E53,S11.E54,S11.E57,S11.E58,S11. ..
In response to seeing our technology for the first time, a member of the Mayo Clinic team told us, “As a citizen on this planet, I want to see this everywhere.”
Jacksonville, Florida (FL), United States
Healthcare
People
Connect with us at
About
In response to seeing our technology for the first time, a member of the Mayo Clinic team told us, “As a citizen on this planet, I want to see this everywhere.”
MicroLumix patented automated disinfection technology, GermPass, has been independently lab tested and shown to kill greater than 99.999% of germs (> 5-log reduction) within a few seconds after virtually every single touch. This proprietary technology is a game-changer for preventing unnecessary deaths and illnesses in healthcare and across the public and private sectors.
The MicroLumix mission is to prevent needless morbidity and mortality, along with the significant financial consequences, caused by contaminated high-volume touchpoints.
GermPass integrates with existing high-volume touchpoints such as elevators, doors, and restrooms, utilizing proprietary patented UVC-enabled technology to deliver a fatal blow to pathogens within a few seconds after every human interaction.
Independently tested by world-renowned environmental microbiologist Dr Charles Gerba’s team at the University of Arizona, GermPass was tested against a panel of 14 potentially lethal pathogens including spores, fungi, viruses, and bacteria. Their analysis revealed that GermPass achieved greater than 99.99931% inactivation of the germs within 7 seconds.
MicroLumix is an industry pioneer, functioning at the forefront of public safety research and technological innovation. Our groundbreaking research, directly tying contaminated HVTs to infectious disease transmission, is irrefutable and will ultimately lead to saving millions of lives each year.
In support of our stated mission, MicroLumix is calling on leadership in both the public and private sectors; healthcare, travel, tourism, entertainment, and industry, to take massive and immediate action to decontaminate public surfaces and prevent the pain and suffering caused through the neglectful avoidance of HVT sanitization.
MicroLumix patented automated disinfection technology, GermPass, has been independently lab tested and shown to kill greater than 99.999% of germs (> 5-log reduction) within a few seconds after virtually every single touch. This proprietary technology is a game-changer for preventing unnecessary deaths and illnesses in healthcare and across the public and private sectors.
The MicroLumix mission is to prevent needless morbidity and mortality, along with the significant financial consequences, caused by contaminated high-volume touchpoints.
GermPass integrates with existing high-volume touchpoints such as elevators, doors, and restrooms, utilizing proprietary patented UVC-enabled technology to deliver a fatal blow to pathogens within a few seconds after every human interaction.
Independently tested by world-renowned environmental microbiologist Dr Charles Gerba’s team at the University of Arizona, GermPass was tested against a panel of 14 potentially lethal pathogens including spores, fungi, viruses, and bacteria. Their analysis revealed that GermPass achieved greater than 99.99931% inactivation of the germs within 7 seconds.
MicroLumix is an industry pioneer, functioning at the forefront of public safety research and technological innovation. Our groundbreaking research, directly tying contaminated HVTs to infectious disease transmission, is irrefutable and will ultimately lead to saving millions of lives each year.
In support of our stated mission, MicroLumix is calling on leadership in both the public and private sectors; healthcare, travel, tourism, entertainment, and industry, to take massive and immediate action to decontaminate public surfaces and prevent the pain and suffering caused through the neglectful avoidance of HVT sanitization.
